Progenics Pharmaceuticals (FRA:PGP) Total Liabilities : €61.30 Mil (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Total Liabilities?

Progenics Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2020 was €61.30 Mil.

Progenics Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2019 (€67.30 Mil) to Dec. 2019 (€65.63 Mil) and declined from Dec. 2019 (€65.63 Mil) to Mar. 2020 (€61.30 Mil).

Progenics Pharmaceuticals's annual Total Liabilities declined from Dec. 2017 (€69.72 Mil) to Dec. 2018 (€60.14 Mil) but then increased from Dec. 2018 (€60.14 Mil) to Dec. 2019 (€65.63 Mil).

Progenics Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Progenics Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Total Liabilities Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Liabilities

Get a 7-Day Free Trial

37.26

89.32

69.72

60.14

65.63

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Total Liabilities	Get a 7-Day Free Trial															71.53	70.85	67.30	65.63	61.30

Progenics Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Progenics Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2019 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.861	+	(42.224	+	3.509
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.031	+	0)
	=	65.63

Total Liabilities	=	Total Assets (A: Dec. 2019 )	-	Total Equity (A: Dec. 2019 )
	=	107.523	-	41.898
	=	65.63

Progenics Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2020 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.285	+	(40.723	+	3.258
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.031	+	0)
	=	61.30

Total Liabilities	=	Total Assets (Q: Mar. 2020 )	-	Total Equity (Q: Mar. 2020 )
	=	89.001	-	27.705
	=	61.30

Progenics Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023